{"id":"NCT03259555","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder","officialTitle":"A Multicenter, Randomized, Double-blind Trial of Brexpiprazole Versus Placebo for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-09-14","primaryCompletion":"2019-01-02","completion":"2019-01-02","firstPosted":"2017-08-23","resultsPosted":"2020-02-10","lastUpdate":"2020-02-10"},"enrollment":322,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar I Disorder","Manic Episode"],"interventions":[{"type":"DRUG","name":"Brexpiprazole","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Brexpiprazole","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To demonstrate the efficacy of brexpiprazole for the acute treatment of manic episodes, with or without mixed features, in participants with a diagnosis of bipolar I disorder.","primaryOutcome":{"measure":"Change From Baseline In Young-Mania Rating Scale (YMRS) Score At Week 3","timeFrame":"Baseline, Week 3","effectByArm":[{"arm":"Brexpiprazole","deltaMin":-10.6,"sd":0.72},{"arm":"Placebo","deltaMin":-10.8,"sd":0.7}],"pValues":[{"comp":"OG000 vs OG001","p":"=0.8797"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":17},"locations":{"siteCount":48,"countries":["United States","Bulgaria","Poland","Serbia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":158},"commonTop":["Headache","Akathisia","Nausea","Constipation","Agitation"]}}